araag2/HINT huggingface dataset:
Clinical trial NCT00216216 (phase 2, status: terminated)
Conditions: small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Reason stopped: 
    the results from the interim analysis were not favorable to continue this trial.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological proof of neuroendocrine cancers (including small cell
             cancers of any site [including lung] or poorly differentiated neuroendocrine cancers
             of the lung with (unidimensionally) measurable disease as per the RECIST criteria

          -  Chemoresistant or chemosensitive disease

          -  Patients must have received treatment with at least one but not more than 2 prior
             chemotherapy regimens, including one regimen containing a platinum agent

          -  Radiation therapy must have completed their radiation at least 14 days prior to being
             registered for protocol therapy, and toxicities due to radiation must have recovered
             to < grade 1 or baseline prior to registration

          -  Negative pregnancy test

        Exclusion Criteria:

          -  No clinically significant infections as judged by the treating investigator

          -  No symptomatic CNS metastasis

          -  No radiation to > 25% of the marrow containing spaces

          -  No previous treatment with pemetrexed

          -  No uncontrolled pleural effusions

          -  No current breastfeeding
Clinical trial NCT00518011 (phase 2, status: completed)
Conditions: non-squamous non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: erlotinib, gemcitabine
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >=18 years of age;

          -  non-small cell lung cancer, stage IIIb (with effusion) or stage IV with measurable
             disease ;

          -  ECOG PS 2;

          -  adequate organ function.

        Exclusion Criteria:

          -  prior chemotherapy or systemic anti-tumor therapy;

          -  hypersensitivity to erlotinib;

          -  any condition contraindicating the use of the study medication and/or impairing the
             interpretation of results and/or leading to treatment-related complications.
Clinical trial NCT01081951 (phase 2, status: active, not recruiting)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: olaparib, paclitaxel, carboplatin, paclitaxel, drug: carboplatin
SMILES: OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with serous ovarian cancer

          -  Patients who have received no more than 3 previous platinum containing treatments and
             were progression free for at least 6 months following the end of the last platinum
             treatment

          -  At least one lesion that is suitable for accurate repeated measurements

        Exclusion Criteria:

          -  Patients receiving any systemic anticancer chemotherapy, radiotherapy (except
             palliative) within two weeks from the last dose prior to study treatment

          -  Hypersensitivity to pre medications required for treatment with paclitaxel/carboplatin
Clinical trial NCT00659802 (phase 2, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: hmpl-004 low dose, placebo, hmpl-004 high dose
SMILES: [H]\C(C[C@]1([H])C(=C)CC[C@]2([H])[C@](C)(CO)[C@]([H])(O)CC[C@@]12C)=C1/C(=O)OC[C@@]1([H])O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H]\C(C[C@]1([H])C(=C)CC[C@]2([H])[C@](C)(CO)[C@]([H])(O)CC[C@@]12C)=C1/C(=O)OC[C@@]1([H])O
Eligibility criteria:

        Inclusion Criteria:

          -  Have active confirmed mild to moderate ulcerative colitis

        Exclusion Criteria:

          -  Diagnosed with Crohn's Disease or
Clinical trial NCT00550004 (phase 2, status: terminated)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: rp101, gemcitabine (1000 mg/m2)
SMILES: [H]\C(Br)=C(\[H])C1=CN(C(=O)N=C1O)[C@@]1([H])C[C@]([H])(O)[C@@]([H])(CO)O1, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must be 18 years of age or older

          -  Not previously treated with chemotherapy for Pancreatic Cancer

          -  ECOG performance status of 0 or 1

          -  Life expectancy > 3 months

          -  Documentation of all sites of pancreatic disease within 28 days prior to randomization

          -  Adequate hematological, renal, and hepatic function

          -  Not pregnant or nursing

          -  Fertile subjects must practice a medically approved method of contraception

        Exclusion Criteria:

          -  Prior history of other malignant tumors

          -  Participation in another investigational study within 4 weeks prior to treatment start

          -  Major surgery within 14 days prior to treatment start

          -  Radiation treatment within 28 days prior to treatment start

          -  Uncontrolled cardiac atrial or ventricular arrhythmias

          -  Gastrointestinal tract disease such resulting in an inability to take oral medication

          -  Known to be seropositive for HIV, HBV, or HCV

          -  Uncontrolled cancer pain
Clinical trial NCT00554086 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: escalating dose of casodex from 50mg daily to 150 mg daily
SMILES: CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          1. Provision of written informed consent.

          2. Men, over 18 years of age, with histologically-confirmed prostate cancer

          3. Treatment with Zoladex (goserelin acetate) for greater than 3 months prior to Day 1

          4. Serum testosterone level < 50 ng/ml

          5. Current treatment with bicalutamide 50 mg daily.**

          6. Two consecutive rises in PSA above a nadir value, with the absolute value of the
             latest PSA > 2.0 ng/ml.

          7. Highest PSA level no greater than or equal to 30 ng/ml.

          8. Life expectancy of greater than 1 year -

        Exclusion Criteria:

          1. Patients may not have received prolonged anti-androgen therapy other than with
             bicalutamide. Patients who have received short term (2 months or less) non-steroidal
             anti-androgen therapy with an agent other than bicalutamide to block flare are not
             excluded.*

          2. PSA level greater than 30 ng/ml.

          3. In the opinion of the investigator, any evidence of severe or uncontrolled systemic
             disease which would make it undesirable for the patient to participate in the trial.

          4. Subjects who have received prior chemotherapy.

          5. Other co-existing malignancies or malignancies diagnosed within the last 5 years with
             the exception of basal cell carcinoma or superficial transitional cell carcinoma of
             the bladder.

          6. Absolute neutrophil count less than 1.5 x 109/L or platelets less than 100 x 109/L.

          7. Serum bilirubin greater than 1.25 times the upper limit of reference range (ULRR).

          8. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2.5
             times the ULRR.

          9. Serum creatinine greater than 1.5 times -
Clinical trial NCT01193361 (phase 2, status: completed)
Conditions: hepatitis c virus
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: bms-791325, bms-791325, placebo, peg-interferon alfa-2a, ribavirin
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects chronically infected with HCV genotype 1 as documented by: positive for
             anti-HCV antibody, HCV RNA, or a positive HCV genotype test at least 6 months prior to
             Screening, and positive for HCV RNA and anti-HCV antibody at Screening

          -  HCV RNA ≥ 10*5* IU/mL at Screening

          -  Less than 4 weeks total prior therapy with an IFN formulation (ie, IFNα, pegIFNα-2a),
             or RBV and no exposure to IFN or RBV within 24 weeks of Randomization

          -  Results of a biopsy obtained ≤ 24 months prior to Randomization showing no evidence of
             cirrhosis

          -  Body Mass Index (BMI) of 18 to 35 kg/m², inclusive. BMI = weight (kg)/ [height (m)]²
             at Screening

        Exclusion Criteria:

          -  Liver transplant recipients

          -  Documented or suspected HCC by imaging or liver biopsy

          -  Evidence of a medical condition associated with chronic liver disease other than HCV
             (such as but not limited to: hemochromatosis, autoimmune hepatitis, metabolic liver
             disease, alcoholic liver disease, toxin exposures)

          -  History of chronic hepatitis B virus (HBV) as documented by HBV serologies (eg.
             HBsAg-seropositive). Patients with resolved HBV infection may participate (eg.
             HBsAb-seropositive)

          -  Current or known history of cancer (except in situ carcinoma of the cervix or
             adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior
             to enrollment
Clinical trial NCT00130390 (phase 2, status: terminated)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: nitazoxanide
SMILES: CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
Reason stopped: 
    terminated due to slow recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥18 years.

          -  Diagnosis of Crohn's disease with colonic or perianal involvement confirmed by
             endoscopic, histologic and/or radiologic data.

          -  CDAI score ≥200 and ≤400.

        Exclusion Criteria:

          -  Subjects known to have stool positive for Clostridium difficile toxin A or B,
             bacterial enteric pathogens, rotavirus, Cryptosporidium species (spp.), and/or
             ova/parasites.

          -  Evidence of bowel obstruction.

          -  Females that are pregnant, breast-feeding or not using birth control and are sexually
             active.

          -  Serious systemic disorders incompatible with the study.

          -  History of hypersensitivity to nitazoxanide or any inactive ingredient in the
             formulation.

          -  Uncontrolled gastro-intestinal bleeding.

          -  Evidence of intestinal abscess, non-perianal fistula or stricture.

          -  Patients who have received antibiotics in the past 7 days.

          -  Patients receiving >20 mg of prednisone, or its equivalent.

          -  Patients receiving Anucort-HC or rectal steroids.

          -  Patients receiving immunosuppressive therapy that has not been stabilized.

          -  Patients who have received TNF-alpha inhibitor treatments such as infliximab or other
             biological agents within three months prior to start of treatment.

          -  Patients with Crohn's disease confined to the esophagus, stomach and small bowel.
Clinical trial NCT01273389 (phase 2, status: completed)
Conditions: lupus nephritis
ICD codes: B26.83, A51.44, N11.8, N11.9, N12
Drugs: cnto 136, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Systemic lupus erythematosus (SLE), and biopsy-proven International
             Society of Nephrology/Renal Pathology Society Class III or IV lupus glomerulonephritis
             within approximately 14 months prior to randomization

          -  Persistently active nephritis defined as, proteinuria greater than 0.5g/day as
             determined by measurement of total urine protein less than 0.5 g/24- hours or a urine
             Protein/Creatinine (P/C) ratio greater than 0.5 (mg/mg) in a timed collection of 12 or
             more hours, for 2 months or more prior to the first administration of study medication
             and observed during at least 2 visits conducted 1 week apart during the screening
             period

          -  Active Class III or Class IV lupus nephritis determined by recent biopsy within
             approximately 6 months prior to screening or at least 1 of the following 3 criteria:
             hematuria (blood in urine), anti-DNA positivity, or low C3 or C4 complement levels

          -  Stable immunosuppression for at least 9 weeks prior to the first administration of
             study medication consisting of MMF 1-3 g/day (or equivalent dose of MPA) with/without
             corticosteroids up to prednisone equivalent of 20 mg/day, or azathioprine 1-3
             mg/kg/day with/without corticosteroids up to prednisone equivalent of 20 mg/day

          -  Stable dose of angiotensin-converting enzyme (ACE) inhibitor/angiotensin II receptor
             blocker (ARB) for at least 9 weeks prior to the first administration of study
             medication

          -  If using oral corticosteroids, must be on a stable dose equivalent to 20 mg/day or
             less of prednisone for at least 9 weeks prior to the first administration of study
             medication

        Exclusion Criteria:

          -  Cyclophosphamide use within 3 months of randomization

          -  B-cell depletion therapy within 6 months of screening, or evidence of persistent
             B-cell depletion at the time of screening

          -  Greater than 50 percent glomerular sclerosis on renal biopsy

          -  Serum creatinine > 2.5 mg/dL (SI: > 177 µmol/L)

          -  White blood cell count < 3.5 x 10^3 cells/µL (SI: < 3.5 x 10^9 cells/L) or neutrophils
             < 1.96 x 10^3 cells/µL (SI: < 1.96 x 10^9 cells/L)

          -  Platelets < 140 x 103 cells/ µL (SI: < 140 x 10^9 cells/L)
Clinical trial NCT00486720 (phase 2, status: terminated)
Conditions: myelodysplastic syndromes, blood disease, bone marrow disease
ICD codes: D46.9, D46.C, D46.Z, Z52.3, T86.01, T86.02, T86.03, Z94.81, C79.52, T86.00
Drugs: vorinostat, vorinostat
SMILES: ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

        Patient is a male or female, at least 18 years of age with low or intermediate-1 risk
        Myelodysplastic Syndrome (MDS) defined by the International Prognostic Scoring System

          -  Patient has previously untreated disease, or has received up to one prior treatment
             regimen for lower-risk Myelodysplastic Syndrome

          -  Patient has a performance status of equal to or less than 2 on the Eastern Cooperative
             Oncology Group Performance Scale

          -  Patient must have adequate organ function

        Exclusion Criteria:

          -  Patient has clinical evidence of Central Nervous System (CNS) leukemia

          -  Patient is pregnant or breastfeeding, or expecting to conceive within the projected
             duration of the study

          -  Patient had prior treatment with a histone deacetylase inhibitor
Clinical trial NCT00402051 (phase 2, status: completed)
Conditions: non-small-cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed, cisplatin, carboplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Cytologically and/or histologically confirmed NSCLC Stage IIIb or IV

          -  No previous systemic chemotherapy for this cancer

          -  At least one uni-dimensionally measurable lesion meeting Response Evaluation Criteria
             In Solid Tumors (RECIST) criteria

          -  Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1 and adequate
             organ function

          -  Prior radiation therapy allowed but limited to <25% of the patient's bone marrow

        Exclusion Criteria:

          -  Serious concomitant systemic disorder or active infection

          -  Mild to moderate renal insufficiency, but unable to interrupt salicylates or other
             nonsteroidal anti-inflammatory drugs

          -  Symptomatic central nervous system (CNS) metastases requiring concurrent
             corticosteroid therapy

          -  Presence of clinically significant third-space fluid collections
Clinical trial NCT00176631 (phase 2, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of prostate adenocarcinoma

               -  Metastatic disease

          -  Must have failed initial hormonal therapy and have disease progression after at least
             one chemotherapy regimen*, meeting any of the following criteria:

               -  Progressive PSA ≥ 5 ng/mL, as evidenced by 2 separate measurements taken ≥ 2
                  weeks apart with the second PSA measurement greater than the first one and PSA
                  measurement at screening greater than the first one

               -  Progressive measurable disease (e.g., changes in the size of lymph nodes or
                  parenchymal masses or appearance of new lesions on physical examination or
                  x-ray/CT scan) with a PSA level at screening ≥ 5 ng/mL

               -  Progressive bone metastasis (e.g., presence of new lesions on a bone scan) with a
                  PSA level at screening ≥ 5 ng/mL NOTE: *Prior chemotherapy must include a taxane
                  therapy, but disease progression does not have to follow taxane therapy

          -  Patients must maintain primary androgen ablation (hormonal) therapy AND experience
             disease progression while not receiving antiandrogen therapy

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Life expectancy ≥ 6 months

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  WBC ≥ 3,500/mm^3

          -  Bilirubin ≤ 1.2 mg/dL

          -  Creatinine ≤ 1.5 mg/dL

          -  SGOT or SGPT ≤ 1.5 times upper limit of normal

          -  No other prior malignancy unless treated with curative intent and free of disease for
             the time period considered appropriate for the specific cancer

          -  No uncontrolled hypertension

          -  No active infections

          -  No known HIV positivity

          -  No uncontrolled medical condition that would preclude study therapy

          -  No diagnosis of major depression or suicidal ideation

          -  No problems with oral absorption

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 4 weeks since prior surgery or radiotherapy and recovered

          -  At least 4 weeks since prior flutamide

          -  At least 6 weeks since prior bicalutamide

          -  No prior or concurrent herbal supplements or thiazide diuretics

          -  No other concurrent investigational or commercial agents or therapies
Clinical trial NCT01026610 (phase 2, status: completed)
Conditions: chronic hepatitis b
ICD codes: B18.0, B18.1, B18.2, B18.8, B18.9
Drugs: lb80380 90 mg, lb80380 150 mg, entecavir 0.5 mg
SMILES: NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C
Eligibility criteria:

        Inclusion Criteria:

          -  Female or male, 18 to 65 years of age, inclusive

          -  Chronic hepatitis B

          -  Not treated with anti-viral therapeutics including interferon or pegylated interferons
             for more than 12 weeks before Screening

          -  Not treated with anti-viral therapeutics including interferon or pegylated interferons
             6 months within Screening

          -  Compensated chronic hepatitis B

          -  HBeAg positive or HBeAg negative

          -  Elevated serum ALT level (1.2-10 X ULN, inclusive)

        Exclusion Criteria:

          -  Co-infection with hepatitis C or D virus (HCV or HDV) or HIV

          -  Decompensated liver disease

          -  Creatinine clearance (calculated by Cockroft-Gault formula) less than 50 ml/min

          -  Screening alpha-fetoprotein (AFP) value greater than or equal to 50 ng/mL, and a
             follow-up ultrasonography performed prior to baseline shows findings indicative of HCC

          -  Treatment with immunomodulatory agent or corticosteroids within 6 months prior to
             study entry.

          -  Pregnancy or breast-feeding

          -  Patient is currently abusing alcohol or illicit drugs

          -  Significant systemic illnesses other than liver diseases

          -  Presence of other causes of liver disease

          -  A history of organ transplantation

        Presence of anti-HBs at screening
Clinical trial NCT00522795 (phase 2, status: completed)
Conditions: esophageal cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: ppx with cisplatin and radiation
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Patients are required to have pathologically confirmed adenocarcinoma or squamous cell
             carcinoma of the esophagus or gastroesophageal junction

          -  Patients may have celiac adenopathy

          -  There must be no evidence of distant organ metastases

          -  No prior chemotherapy or radiation for esophageal cancer

          -  Patients must be > 18 years of age, and non pregnant

          -  Patients must have an ANC > 1,500/ul, platelets > 100,000/ul, creatinine < 2.0 and
             bilirubin < 1.5 x ULN-ECOG performance status 0-1.

          -  Female patients, must either be not of child bearing potential or have a negative
             pregnancy test within 14 days of starting study treatment. Patients are considered not
             of child bearing potential if they are surgically sterile (they have undergone a
             hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are
             postmenopausal. Pregnant or lactating females are not eligible

          -  No contraindications to esophagectomy

          -  Signed informed consent

        Exclusion Criteria:

          -  Active or uncontrolled infection

          -  Patients must not have other coexistent medical condition that would preclude protocol
             therapy.

          -  Any concurrent chemotherapy not indicated in the study protocol or any other
             investigational agent(s).